[
  {
    "ts": null,
    "headline": "Values that Pfizer and Delta CEOs draw on for great leadership",
    "summary": "At Yahoo Finance Invest 2025, Albert Bourla and Ed Bastian shared the values that helped them lead companies through crisis.",
    "url": "https://finnhub.io/api/news?id=f25ee063de3dc00c70ad39ff6c3718b1397a485ead44d83e4e505c71d637b350",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763227823,
      "headline": "Values that Pfizer and Delta CEOs draw on for great leadership",
      "id": 137494647,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "At Yahoo Finance Invest 2025, Albert Bourla and Ed Bastian shared the values that helped them lead companies through crisis.",
      "url": "https://finnhub.io/api/news?id=f25ee063de3dc00c70ad39ff6c3718b1397a485ead44d83e4e505c71d637b350"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer Stock a Buy After This $10 Billion Acquisition?",
    "summary": "The company has been on an acquisition spree for years, and this one may be the most important yet.",
    "url": "https://finnhub.io/api/news?id=ae21000eb759a1f69a4c5c270e5d9f069f038301606cf9933d95265393422669",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763203500,
      "headline": "Is Pfizer Stock a Buy After This $10 Billion Acquisition?",
      "id": 137494733,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The company has been on an acquisition spree for years, and this one may be the most important yet.",
      "url": "https://finnhub.io/api/news?id=ae21000eb759a1f69a4c5c270e5d9f069f038301606cf9933d95265393422669"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's Rich Dividend Story Meets Overpriced Metsera Acquisition/Patent Cliff Risks",
    "summary": "Pfizer offers strong dividends, solid cash flow coverage, discounted value and key risks from patent cliffs, pricing and costly deals. See why PFE stock is a buy.",
    "url": "https://finnhub.io/api/news?id=46a23ae135136beb7707e8dfeadcc19efcadb4a941100d2bf433982c7fee1f65",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763197200,
      "headline": "Pfizer's Rich Dividend Story Meets Overpriced Metsera Acquisition/Patent Cliff Risks",
      "id": 137488194,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359132050/image_1359132050.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer offers strong dividends, solid cash flow coverage, discounted value and key risks from patent cliffs, pricing and costly deals. See why PFE stock is a buy.",
      "url": "https://finnhub.io/api/news?id=46a23ae135136beb7707e8dfeadcc19efcadb4a941100d2bf433982c7fee1f65"
    }
  },
  {
    "ts": null,
    "headline": "A Look at BioNTech (NasdaqGS:BNTX) Valuation Following Pfizer’s Share Sale Announcement",
    "summary": "BioNTech (NasdaqGS:BNTX) shares caught investors’ attention after Pfizer revealed plans to sell its remaining stake in the company through an overnight block trade. This announcement prompted a wave of trading activity and market discussion. See our latest analysis for BioNTech. BioNTech’s share price has edged down nearly 2% this year, with momentum cooling further in recent months as investors weigh Pfizer’s exit and slowing Covid-19 vaccine revenues against a robust pivot back to oncology...",
    "url": "https://finnhub.io/api/news?id=104f9313051b19573208cba8ff04610136e3adef9cf80d9acccd169cd594bb71",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763172645,
      "headline": "A Look at BioNTech (NasdaqGS:BNTX) Valuation Following Pfizer’s Share Sale Announcement",
      "id": 137486729,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BioNTech (NasdaqGS:BNTX) shares caught investors’ attention after Pfizer revealed plans to sell its remaining stake in the company through an overnight block trade. This announcement prompted a wave of trading activity and market discussion. See our latest analysis for BioNTech. BioNTech’s share price has edged down nearly 2% this year, with momentum cooling further in recent months as investors weigh Pfizer’s exit and slowing Covid-19 vaccine revenues against a robust pivot back to oncology...",
      "url": "https://finnhub.io/api/news?id=104f9313051b19573208cba8ff04610136e3adef9cf80d9acccd169cd594bb71"
    }
  }
]